Clinical Trials Directory

Trials / Unknown

UnknownNCT05097664

Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran

Status
Unknown
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
Isfahan University of Medical Sciences · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia. Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.

Detailed description

Investigators will achieved the following data from the participants: 1. Demographic 2. Past medical/habitual history 3. COVID-19 status and related risk factors 4. Mucormycosis status and related risk factors 5. Ocular examination and imaging 6. Follow-up

Conditions

Timeline

Start date
2021-08-23
Primary completion
2021-11-21
Completion
2022-01-20
First posted
2021-10-28
Last updated
2021-10-28

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT05097664. Inclusion in this directory is not an endorsement.